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Abstract
Background: To compare the efficacy of three antiseptic solutions [0.5%, and 1.0% alcohol/chlorhexidine gluconate
(CHG), and 10% aqueous povidone-iodine (PVI)] for the prevention of intravascular catheter colonization, we conducted a
randomized controlled trial in patients from 16 intensive care units in Japan.
Methods: Adult patients undergoing central venous or arterial catheter insertions were randomized to have one of three
antiseptic solutions applied during catheter insertion and dressing changes. The primary endpoint was the incidence of
catheter colonization, and the secondary endpoint was the incidence of catheter-related bloodstream infections (CRBSI).
Results: Of 1132 catheters randomized, 796 (70%) were included in the full analysis set. Catheter-tip colonization incidence
was 3.7, 3.9, and 10.5 events per 1000 catheter-days in 0.5% CHG, 1% CHG, and PVI groups, respectively (p= 0.03). Pairwise
comparisons of catheter colonization between groups showed a significantly higher catheter colonization risk in the PVI
group (0.5% CHG vs. PVI: hazard ratio, HR 0.33 [95% confidence interval, CI 0.12–0.95], p= 0.04; 1.0% CHG vs. PVI: HR 0.35
[95% CI 0.13–0.93], p = 0.04). Sensitivity analyses including all patients by multiple imputations showed consistent
quantitative conclusions (0.5% CHG vs. PVI: HR 0.34, p = 0.03; 1.0% CHG vs. PVI: HR 0.35, p = 0.04). No significant
differences were observed in the incidence of CRBSI between groups.
Conclusions: Both 0.5% and 1.0% alcohol CHG are superior to 10% aqueous PVI for the prevention of intravascular
catheter colonization.
Trial registration: Japanese Primary Registries Network; No.: UMIN000008725 Registered on 1 September 2012
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Background
Catheter-related bloodstream infections (CRBSI) are
serious nosocomial infections associated with high
mortality, prolonged intensive care unit (ICU) stay, and
increased healthcare costs [1–3]. The incidence of
CRBSI reportedly decreased to 0.7 cases per 1000
catheter-days [4], probably due to more widespread use
of a prevention bundle, but further reduction is a mean-
ingful and achievable goal [1].
The current Centers for Disease Control and Preven-
tion (CDC) guidelines for preventing intravascular
catheter-related infections published in 2011 [5] recom-
mends skin preparation using >0.5% chlorhexidine solu-
tion with alcohol before central venous catheter (CVC)
or arterial catheter (AC) placement and during dressing
changes. Although several studies have demonstrated
that chlorhexidine gluconate (CHG) solution decreases
the incidence of CRBSI associated with peripheral ven-
ous catheters, CVCs, and ACs to a greater extent than
10% aqueous povidone-iodine (PVI) [6–10], few high-
quality studies have compared the efficacy of 0.5% and
1% CHG in preventing catheter colonization with that of
10% PVI [11–15]. Furthermore, 2% CHG solutions are
not available in several countries, including Japan.
Therefore, a study to compare 0.5% and 1% CHG with
10% PVI is essential.
To identify the ideal topical antiseptic solution for
clinical use, however, CRBSI itself may not be feasible as
an outcome measure due to the low incidence of CRBSI.
Instead, catheter colonization is a reasonable and dur-
able surrogate endpoint [16] when performing a mean-
ingful study with a minimum number of participants.
For this reason, this study was undertaken to compare
the effectiveness of three topical antiseptic solu-
tions—0.5% CHG, 1% CHG, and 10% PVI—for the pre-
vention of CVC and AC colonization. We hypothesize
that catheter colonization incidence is lower after skin
preparation using 0.5% or 1% CHG compared with the
incidence after using 10% PVI.
Methods
Trial design
This multicenter, open-label, parallel randomized con-
trolled study was conducted in 16 ICUs (1 December
2012 to 31 March 2014) including four university hospi-
tals and 12 general hospitals in Japan. Nine intensive
care units were medical ICUs only and seven were
combined medical-surgical ICUs. The review boards of
all participating institutions approved the study protocol,
and patients/close relatives provided written informed
consent. This study was registered with the Japanese
Clinical Research Registration System of the University
Hospital Medical Information Network (UMIN) (regis-
tration number UMIN000008725).
Patients
All consecutive CVCs and ACs placed in patients
≥18 years old after admission to the ICU for the intra-
venous administration of medications, hemodynamic
monitoring and frequent blood sampling were eligible
for inclusion. Exclusion criteria included: catheters
inserted before ICU admission, catheters inserted for
long-term total parenteral nutrition or chemotherapy for
seven or more days, patients with a history of drug
allergy to the study antiseptic solutions, patients with
systemic adverse events or skin reactions at the catheter
insertion site, and catheters changed using a guidewire.
Intervention/randomization
The enrolled catheters were randomly allocated to the
following three groups according to the antiseptic solution
used for initial and subsequent cutaneous antisepsis: 0.5%
alcohol/CHG solution with 79% ethanol (Maskin Wethanol
Solution 0.5% w/v; Maruishi Pharmaceutical Company,
Osaka, Japan), 1.0% alcohol/CHG solution with 79% etha-
nol (Hexizac AL Solution 1%; Yoshida Pharmaceutical
Company, Tokyo, Japan), and 10% aqueous PVI solution
(10% PVI; Isodine Solution 10%; Meiji Seika Pharma Co.,
Tokyo, Japan). Until the randomized catheter was removed,
a subsequently placed catheter in the same patient was not
included the study. The same antiseptic solution was used
during dressing changes and before catheter removal.
Randomization was stratified by the hospital and catheter
type (CVCs or ACs) using the sealed opaque envelope
method with computer-generated randomized blocks of
nine which was generated at the central institution and not
revealed to the participating patients/physicians/nurses.
Although patients/physicians/nurses were not blinded to
the antiseptic solution group, the microbiologists perform-
ing the catheter-tip cultures and data analyst were blinded
to this information.
Clinical assessment/procedure and bacteriological
methods
The type of catheters and insertion sites in this study
were selected at the discretion of individual physicians.
At the time of conducting the study, silver antiseptic
or antimicrobial-impregnated catheters were unavail-
able in Japan.
Before catheter insertion, the site was prepared using
the allocated antiseptic solution for 30 s and allowed to
dry according to standardized protocols (i.e., CHG 30s;
PVI 2 min). Physicians used maximal barrier precautions
(i.e., sterile gloves, gowns, masks, and large drapes cov-
ering the chest), as per CDC guidelines [5]. After cath-
eter insertion, sterile polyurethane or gauze dressings (if
an exudate was observed) were placed at the insertion
site. The dressings were changed every 7 days for poly-
urethane dressings, every 72 h for gauze dressings, or
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sooner if soiled or wet. No antiseptic-containing dress-
ings were used. Physicians/nurses inspected the insertion
site at ≤24-h intervals for any evidence of infection (e.g.,
erythema, pain, swelling, or purulent discharge).
Catheters were removed if their use was not required
or if a CRBSI was suspected [e.g., fever (temperature of
≥38.5 °C); leukocytosis (leukocyte count ≥14,000 cells/
mm3) without any apparent cause; and/or pus, extensive
erythema, or tenderness at the insertion site]. Before
catheter removal, the same antiseptic solution was used
at the site in an identical manner.
After catheter removal, 5 cm and 1–2 cm of the
distal CVC and AC tips, respectively, were immedi-
ately sent for semi-quantitative culture analysis. The
catheter tip is rolled 5–7 times across a 5% sheep
blood agar plate and then aerobically cultured at 35 °
C–37 °C for 24 h to 7 days [17]. All isolated bacteria
were identified using standard methods. When the
Maki method was unavailable, the sonication tech-
nique was used. Antimicrobial susceptibility testing
was performed according to the recommendations of
the Clinical and Laboratory Standards Institute.
The procedures including skin site preparation and
barrier precautions during catheter insertion and re-
moval, site preparation and dressing method during the
dressing change, and the catheter culture method were
standardized and explained to physicians in all ICUs be-
fore the study began. Video lectures of the standardized
procedures were also distributed to the study ICUs. Def-
initions of study parameters (e.g., acute kidney injury
and diabetes) were standardized in all ICUs before the
study began.
Outcomes
The primary outcome of this study is catheter
colonization incidence per 1000 catheter-days at the
time of catheter removal. Secondary outcomes are
CRBSI incidence, ICU length of stay, hospital mortality,
and antiseptic solution-related adverse events.
Definition of catheter colonization and catheter-related
bloodstream infection
Catheter colonization was defined as ≥15 colony-
forming units (CFUs) in a semi-quantitative catheter tip
culture using the roll-plate technique (i.e., by rolling the
catheter segment across 5% sheep blood agar plate) after
24 h [17]. In the sonication technique, the definition of
catheter colonization was at the discretion of the micro-
biological laboratory at each study institution. In the
absence of colonization at 24 h, the culture was allowed
to grow for up to 7 days. CRBSI was defined according
to the CDC [18] and IDSA [19] guidelines, and the
definition included three major criteria (Additional file 1:
Table S1).
Statistical analysis
In a previous study, the incidence of catheter colonization
with 10% PVI and 0.5% CHG was 24.8% and 15.1%,
respectively, whereas another study reported an incidence
of 10.2% with 1.0% CHG [12, 13]. Based on these findings,
we hypothesized that the incidence of catheter
colonization will be 40% lower with CHG (0.5% or 1.0%)
than with 10% PVI. We assumed that the incidence of
catheter colonization in the PVI group would be 25%. The
sample-size estimation showed that 245 catheters are
required in each of the three arms of this study to ensure
80% power and a two-sided α error of 5%.
The data is presented as the mean with standard
deviation (SD) or median with interquartile range (IQR)
for continuous variables and percentages for categorical
variables. One-way analysis of variance (ANOVA) and
the Kruskal–Wallis test or χ2 test and Fisher’s exact test,
as appropriate, were used for comparison. The incidence
of catheter colonization and CRBSI were compared
among the three groups using the log-rank test. Pairwise
comparisons of the antiseptic solutions were conducted
using a marginal Cox proportional hazards model with a
closed testing procedure, and hazard ratios (HR) and
95% confidence intervals (CIs) were calculated. In the
closed testing procedure, 0.5% CHG vs. 10% PVI was
tested only if 1.0% CHG vs. 10% PVI was significant and
0.5% CHG vs. 1.0% CHG was tested if both were signifi-
cant. For repeated catheter insertions in a single patient,
the correlation between patient factors and catheter
factors should be considered. Therefore, we applied a
marginal Cox regression hazard model to compare the
efficacy of the antiseptic solutions despite low propor-
tion of repeated catheter insertions (13.4%) and a min-
imal intra-class correlation (r = 0.02) as shown in a
previous study [5]. Subgroup analyses by catheter type
(CVCs or ACs) and catheter duration (≥72 h or <72 h)
were planned before commencement of the study and
written in the protocol.
The primary population analyzed in this study is the
full analysis set (FAS), while patients without catheter
colonization data were excluded from the intention-to-
treat (ITT) population (Fig. 1). The groups were com-
pared for differences in catheter site and patient charac-
teristics missing primary outcomes, to evaluate the
degree of randomization. As a sensitivity analysis to
evaluate the impact of the exclusion of patients with
missing data in the primary FAS analysis, multiple
imputation (MI) was performed for the imputed missing
data [20]. Multiple imputation (MI) is a principled
method if the mechanism of missing data is missing at
random. The MI by chained equations, applicable for
imputations of continuous and categorical variables with
a non-monotone missing pattern, was used as an imput-
ation algorithm. The number of imputations in MI was
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100, and the number of burn-ins between each imput-
ation was 200. The incomplete response variables were
catheter colonization (binary) and the duration of
catheterization (continuous; log transformed). The ob-
served covariates in the imputation were the antiseptic
solution (categorical) and type of catheter (binary). In
MI by chained equations, each incomplete variable was
sequentially imputed, given all other variables. Analysis
was performed using PROC MI and PROC MIANA-
LYZE in SAS (SAS Inc, Cary, NC, USA). Planned in-
terim analysis was conducted to recalculate the sample
size after registration of 50 catheters in each group. The
significance level for all tests was two-sided at 5%. All
statistical analyses were performed using SAS, version
9.4 (SAS Inc, Cary, NC, USA).
Results
A total of 1226 catheter placements were reviewed for
eligibility, and the remaining 1132 catheters, after
obtaining informed consent, were randomized to one of
three solutions. Several catheters were excluded because
of withdrawal of informed consent, leaving 998 (88%)
catheters eligible for analysis. However, substantial num-
bers of catheters were not cultured for various reasons
(Fig. 1). Therefore, the FAS analysis is limited to 796
(70%) catheters.
There are no significant differences in the baseline
characteristics among the groups (Table 1). The charac-
teristics of the 202 patients excluded because of the lack
of catheter colonization data are similar among the three
groups and between the FAS population and patients
excluded from the FAS (Fig. 1, Additional file 1: Table S2
and S3). No significant differences in the insertion sites
selected were observed (data not shown). The character-
istics of the catheters are similar among the groups
(Table 2).
The incidence of catheter-tip colonization (per 1000
catheter-days) is 3.7, 3.9, and 10.5 events in the 0.5%
CHG, 1% CHG and 10% PVI groups, respectively
(Table 3 and Fig. 2 (Kaplan–Meier curve) (p = 0.03)).
Pairwise comparison of catheter colonization between
groups shows that the risk is significantly higher in the
10% PVI group (0.5% CHG vs. 10% PVI: HR 0.33, 95%
CI 0.12–0.95, p = 0.04; 1.0% CHG vs. 10% PVI: HR0.35,
95% CI 0.13–0.93, p = 0.04). However, there are no
differences in colonization risk between the 0.5% and
1.0% CHG groups (HR 0.95, 95% CI 0.29–3.13, p = 0.94).
Of all analyzed catheters, 134 (16.8%) were further ran-
domized to the three solutions for second or later
insertions, although the initially placed catheters were
already included in the analysis. A sensitivity analysis for
initially inserted catheters, excluding these 134 catheters,
showed no differences in patient characteristics between
the three groups, and the same conclusion was obtained,
showing superiority of 0.5%/1.0% CHG over 10% PVI, as
confirmed in the FAS analysis (Additional file 1: Table S4).
In another sensitivity analysis conducted with MIs for
evaluation of the impact of missing data, the marginal
Cox proportional hazards model yielded results similar to
those from the FAS analysis (Additional file 1: Table S5).
Fig. 1 Flow chart showing randomization of skin preparation for catheter insertion. CHG chlorhexidine gluconate, FAS full analysis set, ITT
Intention to treat, PVI povidone-iodine
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Subgroup analyses by catheter type (CVCs or ACs)
and duration of catheter placement (≥72 h or <72 h)
show that catheter colonization incidence does not
significantly differ among the groups, regardless of cath-
eter type. However, catheter duration ≥72 h poses a
greater colonization risk in the 10% PVI group than that
in the 0.5% CHG group (Additional file 1: Table S6 and
Additional files 2, 3, 4, 5, 6 and 7: Figure S1A-F).
Since the rates of catheter insertion in the femoral vein
differed among the three antiseptic solutions used, an
additional analysis was conducted excluding catheters
placed in the femoral vein. The results were similar to
those of the primary outcome in this study, which
showed that the rate of catheter colonization increased
in the 10% PVI group compared to the 0.5% and 1%
CHG groups (0.5% CHG vs. 10% PVI: HR 0.35, 95% CI
0.11–0.95, p = 0.04; 1.0% CHG vs. 10% PVI: HR0.37, 95%
CI 0.13–0.97, p = 0.04) (Additional file 1: Table S7).
There are no significant differences in the probability
of developing CRBSI among the groups (3.0 vs. 2.0 vs.
4.9 per 1000 catheter-days in 0.5% CHG, 1.0% CHG, and
10% PVI, p = 0.41) (Table 3). Figure 2 shows the related
Kaplan–Meier plots. Pairwise between-group compari-
sons of CRBSI showed no significant differences, but the
Table 1 Characteristics of study participants
Characteristic All
N = 796
0.5% CHG
N = 261
1.0% CHG
N = 278
10% PVI
N = 257
Age, mean (SD), years 66.2 (16.3) 65.7 (16.3) 65.9 (16.3) 67.1 (16.4)
Gender, male (n, %) 504 (63.3%) 162 (62.1%) 187 (67.3%) 155 (60.3%)
APACHE 2, mean (SD) 21.0 (8.5) 21.0 (8.6) 21.5 (8.6) 20.5 (8.4)
SAPS 2, mean (SD) 49.4 (18.6) 48.5 (19.2) 50.9 (18.2) 48.8 (18.4)
SOFA, mean (SD) 7.2 (4.0) 7.1 (3.9) 7.5 (4.3) 7.0 (3.9)
Comorbidities (n, %)
Immunodeficiency 39 (4.9%) 10 (3.8%) 17 (6.1%) 12 (4.7%)
Steroid administration 90 (11.3%) 32 (12.3%) 35 (12.6%) 23 (9.0%)
Trauma 64 (8.0%) 27 (10.3%) 16 (5.8%) 21 (8.2%)
Cancer 84 (10.6%) 29 (11.1%) 31 (11.2%) 24 (9.3%)
Diabetes 153 (19.2%) 57 (21.8%) 51 (18.4%) 45 (17.5%)
HIV 1 (0.1%) 0 (0%) 1 (0.4%) 0 (0%)
Cirrhosis 40 (5.0%) 13 (5.0%) 14 (5.0%) 13 (5.1%)
Acute kidney injury 245 (30.8%) 85 (32.6%) 81 (29.1%) 79 (30.7%)
Chronic kidney disease 137 (17.2%) 51 (19.5%) 47 (16.9%) 39 (15.2%)
Admission category (n, %)
Medical 645 (81.0%) 203 (77.8%) 231 (83.1%) 211 (82.1%)
Scheduled surgery 23 (2.9%) 9 (3.5%) 5 (1.8%) 9 (3.5%)
Emergency surgery 128 (16.1%) 49 (18.8%) 42 (15.1%) 37 (14.4%)
Infections before catheter insertion (n, %) 448 (56.3%) 150 (57.5%) 162 (58.3%) 136 (52.9%)
Origin of infection (n, %)
Central nervous system 4 (0.5%) 1 (0.4%) 2 (0.7%) 1 (0.4%)
Pulmonary 195 (24.5%) 69 (26.5%) 63 (22.7%) 63 (24.5%)
Cardiovascular 5 (0.6%) 2 (0.8%) 2 (0.7%) 1 (0.4%)
Abdominal 92 (11.6%) 23 (8.9%) 44 (15.8%) 25 (9.7%)
Urinary tract 44 (5.5%) 19 (7.3%) 10 (3.6%) 15 (5.8%)
Skin 14 (1.8%) 7 (2.7%) 3 (1.1%) 4 (1.6%)
Catheter 8 (1.0%) 2 (0.8%) 5 (1.8%) 1 (0.4%)
Others 82 (10.3%) 25 (9.6%) 31 (11.2%) 26 (10.1%)
None 351 (44.2%) 112 (43.1%) 118 (42.5%) 121 (47.1%)
Antibiotics before catheter insertion (n, %) 445 (55.9%) 153 (58.6%) 155 (55.8%) 137 (53.3%)
CHG chlorhexidine gluconate, PVI povidone-iodine, SD standard deviation, APACHE acute physiology and chronic health evaluation, SAPS simplified acute physiology
score, SOFA sequential organ failure assessment, HIV human immunodeficiency virus
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risk exhibits a decreasing trend in the 0.5% and 1.0%
CHG groups (0.5% CHG vs. 10% PVI: HR 0.63, 95% CI
0.18–2.22, p = 0.47; 1.0% CHG vs. 10% PVI: HR 0.41,
95% CI 0.10–1.63, p = 0.20). Similar results were ob-
tained in other subgroup analyses (Additional file 1:
Table S6). A summary of patient characteristics and out-
comes in patients with/without colonization or CRBSI
and antibiotics before catheter insertion are shown in
Additional file 1: Table S8 and S9.
Microorganisms isolated from each colonized catheter
and blood in patients diagnosed with CRBSI are shown
in Additional file 1: Table S10 and S11. There are no sig-
nificant differences in microorganism type that caused
catheter colonization and CRBSI between the groups.
Table 2 Characteristics of the catheters
Characteristic All
N = 796
0.5% CHG
N = 261
1.0% CHG
N = 278
10% PVI
N = 257
P value
Type of catheter (n, %) 0.69
Central venous catheter 285 (35.8%) 93 (35.6%) 95 (34.2%) 97 (37.7%)
Arterial catheter 511 (64.2%) 168 (64.4%) 183 (65.8%) 160 (62.3%)
Insertion site (n, %) 0.10
Central venous catheter
Internal jugular vein 265 (93.0%) 86 (92.5%) 93 (97.9%) 86 (88.7%)
Subclavian vein 11 (3.9%) 5 (5.4%) 1 (1.1%) 5 (5.2%)
Femoral vein 9 (3.2%) 2 (2.2%) 1 (1.1%) 6 (6.2%)
Arterial catheter 0.20
Radial artery 481 (96.0%) 160 (97.0%) 173 (96.1%) 148 (94.9%)
Femoral artery 15 (3.0%) 5 (3.0%) 6 (3.3%) 4 (2.6%)
Dorsalis artery 5 (1.0%) 0 1 (0.6%) 4 (2.6%)
Duration of catheterization, median (IQR), days 3.8 (2.0–6.7) 3.8 (2.1–6.7) 4.0 (2.0–7.0) 3.7 (2.0–6.0) 0.43
Methods for catheter culture (n, %) 0.49
Maki methods 663 (83.3%) 223 (85.4%) 227 (81.7%) 213 (82.9%)
Sonication methods 133 (16.7%) 38 (14.6%) 51 (18.4%) 44 (17.1%)
Dressing (n, %) 0.41
Film 668 (83.9%) 225 (86.2%) 228 (82.0%) 215 (83.7%)
Gauze 128 (16.1%) 36 (13.8%) 50 (18.0%) 42 (16.3%)
CHG chlorhexidine gluconate, PVI povidone-iodine, IQR interquartile range
Table 3 Catheter outcomes: colonization and CRBSI
(a) No. of catheters and incidence per 1000 catheter-days
All
N = 796
0.5% CHG
N = 261
1.0% CHG
N = 278
10% PVI
N = 257
P value
Colonization
Number of catheters (%) 24 (3.0%) 5 (1.9%) 6 (2.2%) 13 (5.1%) 0.07
Incidence per 1000 catheter-days, n (95% CI) 5.8 (3.5–8.2) 3.7 (0.5–6.9) 3.9 (0.8–7.0) 10.5 (4.8–16.3) 0.03
CRBSI
Number of catheters (%) 13 (1.6%) 4 (1.5%) 3 (1.1%) 6 (2.3%) 0.51
Incidence, per 1000 catheter-days, n (95% CI) 3.2 (1.4–4.9) 3.0 (0.1–5.8) 2.0 (0–4.2) 4.9 (1.0–8.8) 0.41
(b) Hazard ratio for each combination of antiseptic solution
Colonization CRBSI
HR (95% CI) P value HR (95% CI) P value
0.5% CHG vs. 10% PVI 0.33 (0.12–0.95) 0.04 0.63 (0.18–2.22) 0.47
1.0% CHG vs. 10% PVI 0.35 (0.13–0.93) 0.04 0.41 (0.10–1.63) 0.20
0.5% CHG vs. 1.0% CHG 0.95 (0.29–3.13) 0.94 1.54 (0.35–6.90) 0.57
CHG chlorhexidine gluconate, PVI povidone-iodine, HR hazard ratio, CI confidence interval, CRBSI catheter-related bloodstream infection
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Systemic and local unknown serious adverse events were
not observed in any of the three groups (Additional file 1:
Table S12).
Discussion
The results of this open-label, randomized controlled
study show that alcohol/0.5% CHG and 1.0% CHG were
superior to aqueous 10% PVI for the prevention of CVC
and AC colonization, but the incidence of CRBSI is simi-
lar among the groups. The use of 10% PVI with cathe-
ters in situ for ≥72 h increases the risk of catheter
colonization, whereas there was no difference in catheter
colonization rates among the three solutions tested for
catheters in place <72 h.
The superiority of alcohol/1% CHG over 10% aqueous
PVI or alcohol/0.5% CHG for the prevention of CRBSI
has not been fully examined [11–14, 21, 22]. Also, no
comparative studies have examined the effect of differ-
ences in CHG concentration. Two studies [13, 14] showed
that alcohol/1.0% CHG is superior to 10% aqueous PVI,
but the studies had significant methodological limitations.
One [13] study was prepared as an abstract for a meeting
in 2001 with no subsequent publication as a full paper.
The other [14] study included patients with hematological
disorders alone. The only study comparing CHG at differ-
ent concentrations was conducted by Valles et al [12],
reporting that both alcohol with 0.5% and aqueous 2%
CHG were associated with a significantly lower incidence
of catheter colonization than 10% PVI. A meta-analysis
published in 2016 [23] evaluated the effects of skin anti-
sepsis as part of CVC care for reducing CRBSIs, catheter
colonization, and patient mortality and morbidity. The
results of subgroup comparisons based on the solution
used, concluded that chlorhexidine solution may reduce
rates of CRBSI and catheter colonization compared with
povidone iodine. However, this study included several
types of CHG solutions, including various concentrations
(0.25–2.0%) of chlorhexidine and diluents (alcohol or
aqueous). To the best of our knowledge, this is the first
randomized control trial to demonstrate the efficacy of
alcohol/1.0% CHG and 0.5% CHG over 10% aqueous PVI
in preventing catheter colonization. The results also sug-
gest non-inferiority of 0.5% CHG to 1.0% CHG.
The results of the present study have several important
implications for clinical practice. This result may be
beneficial in several countries, including Japan, where
2% CHG is not approved for cutaneous application for
the prevention of CRBSI. In addition, it is beneficial for
patients in countries that currently use 2% CHG because
the risk of adverse events (e.g., anaphylaxis) may in-
crease with CHG concentration [24].
This study has several limitations. First, the primary
outcome evaluated is catheter colonization, which is
only a surrogate outcome for CRBSI. The incidence of
CRBSI has decreased with time [4]. Based on this, the
sample size required to demonstrate differences in
CRBSI incidence is enormous, making it difficult to con-
duct the study in a manner that will permit verification of
the effectiveness of various antiseptic solutions. According
to a sample size calculation based on the incidence of
CRBSI in the current study, 8460 catheters would be re-
quired (80% power and a two-sided α error of 5%). How-
ever, it has been reported that there is a strong correlation
between CRBSI and catheter colonization (r = 0.8) [16]. In
a b
Fig. 2 Cumulative catheter colonization and catheter-related bloodstream infection risk (Kaplan–Meier curves). a catheter colonization, b catheter-related
bloodstream infection. CHG chlorhexidine gluconate, PVI povidone-iodine
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fact, many previous studies have not defined CRBSI as the
primary outcome [11, 12, 21]. To our knowledge, the only
study designating CRBSI as a primary outcome is the
CLEAN study [25] published in 2016, in which a total of
5159 catheters were included. Taking feasibility into
consideration, we used catheter colonization incidence as
the primary outcome.
Second, this study was unable to completely fulfill the
ITT analysis because some of the catheter colonization
data was missing after randomization due to self-removal
or contamination of the catheters (Fig. 1). This may have
led to confounding by unknown factors and need of the
competing risk analysis. However, efforts were made to
minimize this by confirming that the demographics of the
excluded patients did not differ between the three groups
and between the FAS and the excluded patients (Add-
itional file 1: Table S2 and S3). We also conducted
between-group comparison, with multiple imputation of
missing data to perform the ITT analysis. The results
using a marginal Cox proportional hazards model were
similar to those obtained using FAS analysis. In the
current study, the multiple imputation analysis is consid-
ered equivalent to the competing risk analysis to avoid
overestimation or underestimation of the true effects. All
these analyses support the robustness of our results.
Third, patient and physician blinding was not possible
because the antiseptic solutions have different colors.
However, a detailed study protocol, including handling
of antiseptic solutions, skin preparation, and catheter
insertion technique was pre-defined, and distributed to
each institution. The data manager at the central
hospital site was in regular communication with each
hospital investigator to ensure compliance with the
study protocol. In addition, the microbiologists involved
in the study were blinded to the solution used. There-
fore, we believe that the lack of blinding did not signifi-
cantly affect the study results.
Fourth, in this study, randomization was performed at
the catheter level and not at the patient level, and this
may have influenced the analysis of repeated measure-
ments. Since 16.8% of the catheters in this study repre-
sent repeat insertions in several patients, the primary
outcome may have been affected because of intra-class
correlations. However, taking a previous large random-
ized controlled study [25] (in which repeated measure-
ments were conducted and the intra-class correlation
was 0.02) into consideration, we believe that the
repeated measurements in this study had little impact
on the results because we were analyzing using a mar-
ginal Cox regression model. We conducted a sensitivity
analysis including only the first catheter inserted in each
patient, and no differences in patient characteristics were
observed among the three groups. The results are simi-
lar to that those obtained using the FAS analysis.
Finally, the effectiveness of alcohol/CHG and PVI-
alcohol were not compared because PVI-alcohol has not
been approved for use in skin disinfection of the cath-
eter insertion site in Japan. It has previously been
reported that alcohol/2% CHG provides greater protec-
tion against short-term catheter-related infections than
PVI-alcohol [25]. Further studies are necessary to verify
differences in the efficacy of alcohol/0.5% or 1.0% CHG
and 5% PVI-alcohol for the prevention of CRBSI.
Conclusions
The results of this trial demonstrate that both alcohol/
0.5% and 1.0% CHG are superior to 10% aqueous PVI
for the prevention of catheter colonization. Hospitals
where higher chlorhexidine concentrations are not per-
mitted can use alcohol/0.5% CHG as an alternative to
alcohol/1% CHG for the prevention of CRBSI. However,
the optimal chlorhexidine concentration for the preven-
tion of CRBSI has not yet been elucidated.
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